Understanding how gut bacteria affect lung disease in cystic fibrosis
Determining How a Dynamic Microbiome Contributes to Cystic Fibrosis Lung Disease
This study is looking at how the bacteria in the lungs of people with cystic fibrosis change during times when their symptoms get worse, to help find better ways to manage lung infections and improve their health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Michigan State University NIH-funded |
| Lab location | 1 site (East Lansing, United States) |
| Project ID | NIH-10448246 on NIH RePORTER |
What this research studies
This research investigates the role of bacterial communities in the lungs of cystic fibrosis patients, particularly during episodes of worsening symptoms known as pulmonary exacerbations. The study aims to understand how shifts in these bacterial populations, especially the increase of anaerobic bacteria, contribute to lung function decline and the need for aggressive antibiotic treatments. By analyzing these dynamics, researchers hope to uncover mechanisms that could lead to better management of lung infections in cystic fibrosis patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with cystic fibrosis who experience recurrent lung infections and pulmonary exacerbations.
Not a fit: Patients without cystic fibrosis or those who do not experience pulmonary exacerbations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies that better manage lung infections and enhance the quality of life for cystic fibrosis patients.
How similar studies have performed: Previous research has shown that understanding the microbiome can significantly impact treatment approaches in chronic lung diseases, suggesting potential success for this study's approach.
Where this research is happening
East Lansing, United States
- Michigan State University — East Lansing, United States (Active)
Researchers
- Principal investigator: Quinn, Robert Andrew — Michigan State University
- Study coordinator: Quinn, Robert Andrew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.